Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen

Research output: Contribution to journalArticle


  • A Isaac
  • S Taylor
  • E Smit
  • SE Gihbons
  • DJ White
  • SM Drake
  • S Khoo
  • DJ Back


Objectives: To evaluate the steady-state blood plasma (BP), CSF and seminal plasma (SP) pharmacokinetics (PK) of twice-daily indinavir 400 mg and lopinavir/ritonavir. Methods: Ten HIV-1-positive men on lopinavir/ritonavir participated in a PK study. PK sampling was performed before and 2 weeks after adding indinavir to lopinavir/ritonavir-containing regimens. BP, CSF and SP RNA levels, CD4 counts and blood chemistry were checked at baseline and 2 weeks after indinavir. Results: At baseline: lopinavir parameters (n=10) in BP were within expected levels. Median lopinavir trough concentrations (n=5) in CSF and SP were below the limit of detection (BLD) (i.e. 80 ng/mL in seven of eight plasma samples, and all CSF and semen samples collected.


Original languageEnglish
Pages (from-to)498-502
Number of pages5
JournalJournal of Antimicrobial Chemotherapy
Issue number2
Publication statusPublished - 1 Aug 2004


  • drug interactions, double boosted, protease inhibitors, HIV, sanctuary sites